

**Terms and Conditions**

The Waisman Center and WiCell Research Institute, Inc. offer a collaborative service to derive and characterize induced pluripotent stem cell (iPSC) lines for the benefit of researchers engaged in stem cell research at the University of Wisconsin – Madison.

*Waisman Center*

Cell reprogramming from biopsy tissue, banked or fresh fibroblasts or blood samples will be carried out by the iPSC service of the Waisman Center Cellular and Molecular Neuroscience (WC CMN) Core under the direction of Dr. Su-Chun Zhang, MD, PhD. All projects must obtain prior institutional IRB approval (human subjects, biosafety, stem cells, if applicable). In addition, funding information must be provided prior to initiation of reprogramming.

Researcher will provide the Waisman iPSC service with sufficient quantities of the sample materials with which to perform the reprogramming. Waisman Center will use reasonable care in handling and storing samples, but shall not be held responsible for any loss or destruction thereof.

The Waisman Center staff will use reasonable efforts to successfully complete the reprogramming, using due care in accordance with generally prevailing applicable industry standards, taking into consideration our level of experience in the techniques required. Due to the experimental nature of the materials provided to the Waisman Center by the researchers, delays in performing the reprogramming services or the inability to complete the services, which are not unreasonable under comparable industry standards, shall not be the cause of any claim against the Waisman Center.

*WiCell*

(Optional) Characterization of iPSCs will be carried out by WiCell under their terms and conditions. The Waisman iPSC service will deliver iPSC clones directly to WiCell. Distribution of cell lines is also available from WiCell as a no-cost option, but is not required. The terms of any such distribution of cell lines is outside of the scope of the iPSC Services, and will be documented by a separate agreement to be entered into by WiCell and the Researcher. Revenue sharing from cell line distribution will be shared between the researcher and Waisman Center.

Please contact Anita Bhattacharyya, Ph.D. at [ipsc@waisman.wisc.edu](mailto:ipsc@waisman.wisc.edu) with questions or concerns.

**1 –Investigator Information**

Name: \_\_\_\_\_

Institute/Center: \_\_\_\_\_

Primary contact for these cells: \_\_\_\_\_

Phone: \_\_\_\_\_ Email: \_\_\_\_\_

**2 – Research project details**

Project Title: \_\_\_\_\_

Brief summary of Research:

**3- Funding**

Grant/project number for billing: \_\_\_\_\_

Waisman Center Investigator?  YES  NO

If yes, is this grant/project on Waisman Center core grant?  YES  NO

UW SCRMC member?  YES  NO

**4- Tissue/cell source -biosafety and human subjects**

Indicate the species and tissue source of the biopsy/cells (human, non-human primate) \_\_\_\_\_

Will you be providing **cells** for reprogramming?  YES  NO

Cell line name: \_\_\_\_\_

Indicate genetic mutation, if any: \_\_\_\_\_

Will you be providing **a biopsy** for reprogramming?  YES  NO

Source of biopsy (organ, institution) \_\_\_\_\_

Will you be providing **a blood sample** for reprogramming?  YES  NO

Human subjects IRB approval for blood collection?  YES  NO  
(Please provide documentation of IRB approval)

Indicate genetic mutation, if any: \_\_\_\_\_

Does the biopsy or cell sample(s) contain any known infectious agent(s)?  YES  NO  I don't know

If YES list agent(s) and provide agent biosafety level using classifications as listed in "Biosafety in Microbiological and Biomedical Laboratories", US Department of Health and Human Services, 4th edition.

Is the sample negative for Mycoplasma?  YES  NO  I don't know

ALL samples will be tested upon receipt. WC iPSC Service will not process any samples that test positive for mycoplasma.

**5-Human Pluripotent Stem Cell Responsibilities**

By signing this form, you confirm that the human induced pluripotent stem cells **will not** be used for the following:

- Research in which human induced pluripotent stem cells are introduced into nonhuman primate blastocysts.
- Research involving the breeding of animals where the introduction of human induced pluripotent stem cells may contribute to the germ line.

**6-Core Grant Acknowledgement**

Please acknowledge the Waisman Center U54 Core grant in any publications that result from projects performed within the CMN Core laboratory or with the assistance of CMN Core personnel. "This study was supported in part by a core grant to the Waisman Center from the National Institute of Child Health and Human Development (U54 HD090256)."

**INVESTIGATOR ACKNOWLEDGEMENT OF RESPONSIBILITY**

**I certify that the information provided herein is correct. I ensure that my researchers are aware of and will conform to the policies listed above.**

\_\_\_\_\_  
Signature (Principal Investigator) \_\_\_\_\_ Date

PROCEDURE	UW CHARGES
Waisman iPSC core biopsy to fibroblasts	\$1,000
Waisman iPSC core reprogramming(episomal)	\$5,500
WiCell characterization and banking ( <i>Optional</i> )	\$1,750
<b>Cost to UW investigator</b>	<b>\$8,250</b>

Please contact Anita Bhattacharyya, Ph.D. at [ipsc@waisman.wisc.edu](mailto:ipsc@waisman.wisc.edu) with questions or concerns. Some projects are eligible for subsidies depending on various factors. If you have any questions regarding your project's subsidy, please contact Jody Bleck at [bleck@waisman.wisc.edu](mailto:bleck@waisman.wisc.edu).

PROCEDURE	UW CHARGES
Waisman iPSC core blood sample processing	\$250
Waisman iPSC core reprogramming (Sendai)	\$7,500
WiCell characterization and banking ( <i>Optional</i> )	\$1,750
<b>Cost to UW investigator</b>	<b>\$9,500</b>